Status:
ACTIVE_NOT_RECRUITING
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
Lead Sponsor:
Hannover Medical School
Conditions:
Hepatitis D
Hepatitis B
Eligibility:
All Genders
Brief Summary
Portal hypertension (PH) is one of the key drivers of clinical deteoration in patients with liver cirrhosis. It has been demonstrated that antiviral therapy in patients with chronic hepatitis C infect...
Eligibility Criteria
Inclusion
- Chronic HBV/HDV Coinfection
- suspected or diagnosed liver cirrhosis, indication for hepatovenous pressure gradient (HVPG) measurement or liver cirrhosis and HVPG measurement conducted in the past 12 months (conducted prior to antiviral treatment)
- indication for antiviral treatment with Bulevirtide
- age \>18years
- Must be willing to participate in the study and provide written informed consent
Exclusion
- patient rejects study participation
- no conducted or no indication for HVPG measurement
- age \<18years
Key Trial Info
Start Date :
May 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04863703
Start Date
May 7 2021
End Date
December 31 2026
Last Update
September 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hannover Medical School
Hanover, Lower Saxony, Germany, 30625